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Gastric cancer (GC) was the most frequent type 
of malignant neoplasm worldwide in the 1980s. Although 
its incidence has gradually declined in recent years, today 
GC still is on the fourth place after lung, breast and 
bowel cancers (14.9 new cases per 100,000 in 2010) [1]. 
In Ukraine GC is third after lung and skin cancer among 
men and sixth after breast, skin, endometrial, intestinal 
and cervical cancer among women. 
GC still has a very high mortality rate (second af-
ter lung cancer) with 11,4 deaths per 100,000, which 
continuously declines during last decades. Such high 
mortality rate is caused by the fact that GC is often 
diagnosed during late (ІІІ–ІV) stages, when tumor 
becomes resistant to chemo- and radiotherapy [2, 3].
It is known that patients with tumors of the same 
stage and histological type show totally different re-
sponse to therapy. That is why it is important to find 
molecular markers which are associated with different 
aspects of tumor growth and differentiation that would 
help to predict the disease outcome [1, 4].
Changes in apoptosis and activation of signal 
cascades are vitally important for tumors. Wild type 
р53 is able to activate DNA repair proteins when DNA 
has sustained damage, induce growth arrest by hold-
ing the cell cycle at the G1/S regulation point on DNA 
damage recognition or initiate apoptosis if DNA damage 
proves to be irreparable. The mutant form of this protein 
(tp53) is unable to carry out its functions. Such changes 
in p53 structure are observed in more than 50% of tu-
mors of different origin. Another important regulator 
of apoptosis is BCL-2 protein which has an ability to in-
activate different proapoptotic proteins [1, 2].
EGFR and HER-2/neu are tyrosine kinase receptors 
from the ErbB family which are often overexpressed 
on the tumor cell membrane. These receptors are 
activated by different ligands by homo- or heterodi-
merisation. The signal from intracellular tyrosine kinase 
domain is then transduced to the NF-κB, AKT and 
ERK signal pathways, phosphatydilinositol-3-kinase 
or phospholipase C, what causes changes in apop-
tosis, cell division and differentiation [5].
Adhesion cell contacts formed by cadherin-catenin 
complex (Е-cadherin, α- β- and γ-catenins) play 
important role in GC growth. Intracellular domains 
of E-cadherin are bound to β-catenin, γ-catenin and 
p120ctn protein forming a cytoplasm cell adhesion 
complex, which is necessary for formation of adhesive 
cellular junctions. β-catenin and γ-catenin are also 
bound to α-catenin, which connects cadherin-catenin 
complex with actin cytoskeleton. Loss of any of these 
proteins increases the risk of appearance of local 
or distant metastases [2, 6].
Vascular endothelial growth factor (VEGF) induces 
formation of protrusions in vascular walls, through 
which proteins could move out of the blood vessels. 
As a result, extravascular fibrin gel which mediates 
growth of endothelial cells, is formed. This causes 
blood vessels to grow into the tumor body, thus pro-
moting its growth. On the other hand, tumor which 
has high microvessel density could be more sensitive 
to chemotherapy [1–3].
So, the aim of the study was to perform complex 
study of relations between clinico-morphological prog-
nostic factors and expression of regulators of apop-
tosis (p53, bcl-2), tyrosinkinase receptors (EGFR, 
HER-2/neu), adhesion molecules (E-cadherin, α- and 
β-catenins) and VEGF.
We have analyzed tumor samples from 150 GC pa-
tients using classic immunohistochemical method. Sex, 
age of Gc patients and GC stage distribution correspond-
ed to the statistical data for the Ukrainian population. 
Differences between groups were studied using Stu-
dent’s t-test, correlations were studied with computing 
Pierson’s (r) and Chuprov’s (K) correlation coefficients.
On the first stage of the study we have analyzed 
an expression of regulators of apoptosis, tyrosine 
kinase receptors, markers of cell adhesion and 
neoangiogenesis in relation to generally accepted 
clinico-morphological tumor features (stage, depth 
of invasion, local and distant metastases).
We revealed that 75.4 ± 4.0% of stage IV GC pa-
tients showed positive nuclear reaction with mAb spe-
cific to tp53, while only 24.1 ± 5.6 and 31.5 ± 4.4% 
of patients with stage II and stage III GC, respectively, 
had tp53-positive tumors (Table 1). In the meantime 
Bcl-2 expression was predominantly found in tumors 
of stage II patients (72.4 ± 5.8 vs. 14.8 ± 3.4 % and 
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15.8 ± 3.4% for stage III and IV, respectively). Also 
we have found moderate correlation between the stage 
of the disease according to TNM and tp53 (K=0.34, 
p<0.01) and Bcl-2 (K=0.32, p<0.01) expression. 
Another interesting finding was moderate correlation 
(r=0.32, p<0.01) between the presence of Bcl-2 pro-
tein and absence of tp53 in the tumor.
Table 1. Correlations between expression of molecular markers of apop-
tosis, angiogenesis, cell adhesion and tyrosine kinase receptors in GC tu-
mors and TNM stage of the disease
 Marker
Stage
K Р% of positive tumors
II III IV
p53 24.1 ± 5.6 31.5 ± 4.4 75.4 ± 4.0 0.34 <0.01
Bcl-2 72.4 ± 5.8 14.8 ± 3.4 15.8 ± 3.4 0.32 <0.01
E-cadherin 79.3 ± 5.3 40.7 ± 4.7 36.8 ± 4.5 0.31 <0.01
α-catenin 51.7 ± 6.5 31.4 ± 4.4 29.8 ± 4.2 0.15 >0.05
β-catenin 37.9 ± 6.3 27.7 ± 4.3 24.5 ± 4.0 0.08 >0.05
EGFR 34.4 ± 6.2 29.6 ± 4.3 33.3 ± 4.4 0.06 >0.05
Her-2/neu 17.2 ± 4.9 27.7 ± 4.3 49.1 ± 4.6 0.30 <0.01
VEGF 24.1 ± 5.6 29.6 ± 4.3 71.9 ± 4.2 0.34 <0.01
We also found that Е-cadherin, α- and β-catenin 
expression in GC tumors was often associated with 
earlier stages of the disease. Particularly, 79.3 ± 5.3 % 
of stage II tumors were E-cadherin-positive (K=0.31), 
51.7 ± 6.5% — α-catenin-positive and 37.9 ± 6.3% — 
β-catenin-positive. Statistical analysis showed sig-
nificant correlations only between the GC stage and 
E-cadherin expression (K=0.31, p<0.01).
Other markers that showed significant differences 
between different GC stages were Her-2/neu and 
VEGF. Presence of both of these proteins in tumors 
were associated with the stage IV of the disease (49.1 ± 
4.6 and 71.9 ± 4.2% of positive tumors, respectively). 
We also showed moderate correlation between VEGF 
expression and tumor stage (К=0.34, p<0.05).
Next, we have studied the expression of mentioned 
proteins in relation to parameters on which TNM 
classification is based: T (depth of gastric wall inva-
sion), N (local metastases), M (distant metastases). 
We didn’t observe any significant differences in expres-
sion of studied proteins in relation to M status because 
of very small group of M-positive patients (n = 16).
We found that both studied regulators of apoptosis 
(tp53 and Bcl-2) and VEGF were expressed mostly 
in lymph-node positive GC tumors (55.2 ± 2.6%, 48.4 ± 
2.4% and 51.3 ± 2.4%, respectively). Also, we ob-
served increase of Her-2/neu expression from 28.5 ± 
1.7% in N0 tumors to 40.5 ± 2.1% in tumors with N2. 
On the other hand, E-cadherin, α- and β-catenin–posi-
tive tumors were present in patients without regional 
lymph node metastases (74.6 ± 3.1% for E-cadherin 
and 61.9 ± 2.5% for α-catenin). We found moderate 
correlations between E-cadherin (K=0.45, p<0.05), 
α-catenin (K=0.41, p<0.05), and VEGF (K=0.41, 
p<0.01) expression and lymph node status. 
The only protein, which expression significantly dif-
fered between groups of patients with different T-stage 
tumors was VEGF. Its expression correlated (K=0.32, 
p<0.01) with T4 stage of gastric wall invasion (68.9 ± 
3.2% of positive tumors).
Another significant criterion in diagnostics of neo-
plasms of any localization is their morphological inves-
tigation. Today Lauren’s GC classification [7] is often 
used in clinical practice, according to which two types 
of the disease are diagnosed: intestinal (slow growth, 
high degree of differentiation) and diffuse (faster 
growth, lower degree of differentiation).
We have found (Table 2) that E-cadherin and 
β-catenin were associated with GC of intestinal type 
(78.7 ± 5.0 and 63.6 ± 5.9%, respectively) which 
is thought to be more favorable in prognosis because 
of higher sensitivity to chemotherapy. Also positive 
expression of both studied tyrosine kinase receptors 
was related to this histological type of GC (69.7 ± 5.6% 
for EGFR and 72.7 ± 5.4% for Her-2/neu). Statistical 
analysis showed moderate correlations between E-
cadherin (r=0.36, p<0.01), β-catenin (r=0.39, p<0.01), 
EGFR (r=0.42, p<0.01) and Her-2/neu (0.50, p<0.01) 
expression and histological type of tumor. On the other 
hand, tp53 and VEGF positive expression were markers 
of diffuse GC type (r=0.48 and r=0.19, respectively).
Table 2. Correlations between expression of molecular markers of apop-
tosis, angiogenesis, cell adhesion and tyrosinkinase receptors in GC tu-
mors and histological type of the disease
Marker
Histological type of tumor
r р% of positive tumors
Intestinal type Diffuse type 
р53 17.9 ± 2.5 72.7 ± 5.4 0.48 <0.01
Bcl-2 54.5 ± 6.1 46.1 ± 3.2 0.05 <0.01
E-cadherin 78.7 ± 5.0 34.1 ± 3.1 0.36 <0.01
α-catenin 42.4 ± 3.0 31.6 ± 6.0 0.08 <0.01
β-catenin 63.6 ± 5.9 18.8 ± 2.5 0.39 <0.01
EGFR 69.7 ± 5.6 20.5 ± 2.6 0.42 <0.01
Her-2/neu 72.7 ± 5.4 22.2 ± 2.7 0.50 <0.01
VEGF 39.3 ± 5.9 63.6 ± 3.1 0.19 <0.01
One of the main prognostic criteria of treatment 
efficiency is the duration of the survival period. 
We divided tumor samples into three groups according 
to the length of patient survival period (Group 1 — less 
than 12 months, Group 2 — 12–36 months and Group 
3 — more than 36 months).
We showed that tumors from the patients from the 
Group 1 expressed VEGF (64.9 ± 3.9 %), Bcl-2 (41.5 ± 
3.9%) and tp53 (67.5 ± 3.7%) and were mostly E-
cadherin and α-catenin negative (16.8 ± 3.0% and 
19.4 ± 3.1% of positive tumors, respectively). Patients 
from the Group 2 were characterized by increased 
number of Е-cadherin-positive (up to 66.6 ± 4.9%) and 
α-catenin-positive (31.1 ± 4.8%) tumors, while number 
of VEGF-positive tumors decreased (24.4 ± 4.5%). 
The Group 3 of patients was characterized by highest 
percent of E-cadherin- and α-catenin-positive tumors 
(82.1 ± 5.1 % and 78.5 ± 5.4 %). Also, low and mode-
rate β-catenin, Her-2/neu and EGFR expression were 
observed in all three groups of patients.
We found correlations between tp53 (K=0.34, 
p<0.01), Bcl-2 (K=0.30, p<0.01), E-cadherin (K=0.48, 
p<0.01), α-catenin (K=0.39, p<0.01) and VEGF 
(K=0.35, p<0.01) and length of the survival period.
We also built Caplan — Meier survival curves 
(Figure) for groups of patients with tumors positive 
or negative by each studied marker. Analysis of these 
curves confirmed the results mentioned above and 
showed that patients with tp53-negative, Bcl-2-neg-
ative, E-cadherin-positive, α-catenin-positive and 
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VEF-negative tumors had significantly longer overall 
survival period while we did not observe significant 
differences between patients with β-catenin, EGFR 
and Her-2/neu-positive and negative tumors.
Multifactor Cox analysis (Table 3) showed that 
р53, Bcl-2, Е-cadherin, α-catenin and VEGF positive 
expressions could be used as independent prognostic 
factors. Particularly, Е-cadherin and α-catenin positive 
expression, as well as loss of р53, Bcl-2 and VEGF 
expression are markers of favorable disease prognosis 
and correlates with longer survival period.
Table 3. Multifactor Cox analysis of studied markers
Marker β Р
р53 -0.33 <0.05
Bcl-2 -0.28 <0.05
E-cadherin  0.46 <0.05
α-catenin 0.51 <0.05
β-catenin -0.10 >0.05
Her-2/neu -0.14 >0.05
EGFR -0.08 >0.05
VEGF -0.36 <0.05
In conclusion, we showed strong correlation be-
tween expression of р53, Bcl-2, Е-cadherin, Her2/
neu and VEGF in tumor cells and the stage of disease 
according to TNM classification. We observed the 
highest percent of р53, Her-2/neu and VEGF positive 
tumors in group of stage IV GC patients, while high 
levels of Bcl-2 and E-cadherin were observed in tumors 
of stage II GC patients. GC patients with Т4 degree 
of gastric wall invasion show tendency to increased 
percent of Bcl-2- and VEGF-positive tumors. Also 
we showed that E-cadherin expression correlated with 
absence of lymph node metastases and is observed 
primarily in GC patients with II stage. β-catenin ex-
pression is more often observed in GC tumors without 
distant metastases, while VEGF expression correlated 
with T-stage and presence of metastases in regional 
lymph nodes. Expression of some molecular markers 
is associated with histological type and degree of tumor 
differentiation. We observed increase of E-cadherin, 
α-catenin, EGFR and Her2/neu-positive tumors in the 
group of patients with intestinal type of GC. Tumors 
of diffuse type often expressed р53 та VEGF. We proved 
that the presence of р53, Bcl-2, Е-cadherin, α-catenin 
and VEGF could be used as independent prognostic 
markers of survival for GC patients: high Е-cadherin, 
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Figure. Caplan — Meier survival curves for GC patients with tumors positive and negative by E-caddherin (A), α-catenin (B), tp53 (C), 
Bcl-2 (D), VEGF (E) and EGFR (F) expression. Curves were compared using Wilcoxon U-test
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α-catenin and low р53, Bcl-2 and VEGF expression 
in tumor cells point on favorable prognosis of disease 
outcome with significantly longer survival period.
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